Quick Answer
CERO THERAPEUTICS HOLDINGS, INC. reported Stockholders Equity of -$1.89 million for the year ending 2024.
- CERO THERAPEUTICS HOLDINGS, INC. showed an increase of +95.5% in Stockholders Equity from 2023 to 2024.
- This data is from CERO THERAPEUTICS HOLDINGS, INC.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2021 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $24.0 thousand | Q3 2021: $24.0 thousand | Q1 2022: -$8.05 million | Q2 2022: -$8.16 million | Q3 2022: -$9.06 million | Q1 2023: -$11.58 million | Q2 2023: -$13.29 million | Q3 2023: -$13.77 million | Q1 2024: -$3.98 million | Q2 2024: -$2.48 million | Q4 2024: -$1.89 million | Q1 2025: -$329.4 thousand | Q2 2025: -$1.63 million | Q3 2025: -$4.54 million.
- Historical annual values: Fiscal year 2024: -$1.89 million | Fiscal year 2023: -$42.06 million | Fiscal year 2022: -$11.00 million | Fiscal year 2021: -$7.67 million | Fiscal year 2021: $0.00.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: